DexCom, Inc. (DXCM)

Dexcom's profit beats estimates on strong glucose monitor demand

Dexcom beat Wall Street expectations for first-quarter profit on Thursday, helped by strong demand for a new version of its continuous glucose monitors, but its shares slid 7% after the bell as annual sales forecast was largely below estimates. The company and rival Abbott currently dominate the market for continuous glucose monitors — the devices that track blood glucose levels every few minutes without the need for finger stick tests. Dexcom's total revenue rose 24% to $921 million for the three months ended March 31, beating analysts' average estimate of $909.24 million, according to LSEG data.